RT Journal Article
SR Electronic
T1 Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002673
DO 10.1136/jitc-2021-002673
VO 9
IS 7
A1 Victoria Roulstone
A1 David Mansfield
A1 Robert J Harris
A1 Katie Twigger
A1 Christine White
A1 Johann de Bono
A1 James Spicer
A1 Sophia N Karagiannis
A1 Richard Vile
A1 Hardev Pandha
A1 Alan Melcher
A1 Kevin Harrington
YR 2021
UL http://jitc.bmj.com/content/9/7/e002673.abstract
AB Background Oncolytic reovirus therapy for cancer induces a typical antiviral response to this RNA virus, including neutralizing antibodies. Concomitant treatment with cytotoxic chemotherapies has been hypothesized to improve the therapeutic potential of the virus. Chemotherapy side effects can include immunosuppression, which may slow the rate of the antiviral antibody response, as well as potentially make the patient more vulnerable to viral infection.Method Reovirus neutralizing antibody data were aggregated from separate phase I clinical trials of reovirus administered as a single agent or in combination with gemcitabine, docetaxel, carboplatin and paclitaxel doublet or cyclophosphamide. In addition, the kinetics of individual antibody isotypes were profiled in sera collected in these trials.Results These data demonstrate preserved antiviral antibody responses, with only moderately reduced kinetics with some drugs, most notably gemcitabine. All patients ultimately produced an effective neutralizing antibody response.Conclusion Patients’ responses to infection by reovirus are largely unaffected by the concomitant drug treatments tested, providing confidence that RNA viral treatment or infection is compatible with standard of care treatments.Data are available on reasonable request. Data are available on request from the corresponding author.